ReviewThe Lancet regional health. Southeast Asia2024
Uniqueness of lung cancer in Southeast Asia.
Review in The Lancet regional health. Southeast Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial.British journal of cancer · 2025Trial
- The shifting burden of tracheal, bronchus and lung cancer in ageing Asia: structural drivers and projections to 2050.Annals of medicine · 2026Article
- Mediastinal over-staging with PET-CT in tuberculosis-endemic locally advanced NSCLC: SUV threshold recalibration improves PET/EBUS concordance.European journal of nuclear medicine and molecular imaging · 2026Article
- Brief Report: Translating Selection Criteria for Lung Cancer Screening to an Indian Context-An Analysis From a Tertiary Health Centre.JTO clinical and research reports · 2026Article
- Targeting RAB27A-mediated small extracellular vesicle secretion via CRISPR-Cas9 negatively affects proliferation and metastasis in both in vitro and in vivo SCLC models.Cancer gene therapy · 2026Article
- Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer.Cancers · 2026Review
- Pharmacogenomics in oncology: mutation-targeted therapy and biomarker integration in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Air pollution and lung cancer in India: an escalating public health crisis.International health · 2026Article
- Integrating machine learning-based molecular design with experimental validation for the discovery of EGFR inhibitors in lung cancer.Molecular diversity · 2026Article
- Cancer pattern in Bhutan (2014-2022): Findings from population-based cancer registry-A pathway to monitor cancer control activities.International journal of cancer · 2026Article
- Precision Medicine in Treating Lung Cancer: A Narrative Review on Treatments Targeting Oncogenic Genetic Mutations.Cureus · 2026Review
- Bacterial taxa associated with lung cancer cases in Southeast Asians: a pilot case-control study.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Mitocurcumin induces ROS-/JNK-mediated paraptosis to overcome chemoresistance in non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Applying biotechnology to overcome cancer drug resistance and improve public health outcomes.Osong public health and research perspectives · 2026Article
- Personalised neoantigen vaccines for precision oncology in Southeast Asia: clinical opportunities, infrastructure challenges, and policy perspectives.Frontiers in immunology · 2026Review
- Survival analysis of different treatment modalities and associated outcomes for canine primary pulmonary carcinoma.Frontiers in veterinary science · 2026Article
- Review
- Implementation of circulating tumor DNA (ctDNA) testing in precision oncology: A four-year experience from a tertiary cancer center in India.The journal of liquid biopsy · 2025Article
- Spectrum of rareNarra J · 2025Observational
- Natural history models for lung Cancer: A scoping review.Lung cancer (Amsterdam, Netherlands) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer varies between Caucasians and Asians. There have been differences recorded in the epidemiology, genomics, standard therapies and outcomes, with variations according to the geography and ethnicity which affect the decision for optimal treatment of the patients. To better understand the profile of lung cancer in Southeast Asia, with a focus on India, we have comprehensively reviewed the available data, and discuss the challenges and the way forward. A substantial proportion of patients with lung cancer in Southeast Asia are neversmokers, and adenocarcinoma is the common histopathologic subtype, found in approximately a third of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.